On June 4, 2026 Artera, the developer of multimodal artificial intelligence (MMAI)-based prognostic and predictive cancer tests, reported the clinical availability of the ArteraAI Prostate Test (mHSPC), the first digital pathology–based prognostic test designed to help inform treatment planning for patients with metastatic hormone‑sensitive prostate cancer (mHSPC).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
mHSPC is a diverse disease state with widely variable outcomes, requiring complex treatment decisions that can significantly impact both survival and quality of life. While traditional clinical factors provide general prognostic insight, they do not offer individualized risk. The ArteraAI Prostate Test (mHSPC) addresses this gap by delivering a patient‑specific estimate of 5‑year prostate cancer–specific mortality (PCSM) in patients treated with androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI).
"Artera’s platform was built to bring greater clarity to cancer treatment decisions," said Andre Esteva, CEO of Artera. "With our expansion into metastatic hormone-sensitive prostate cancer, we are excited to leverage our validated MMAI approach for a more complex stage of disease, helping guide treatment decisions with greater confidence."
The ArteraAI Prostate Test (mHSPC) builds on Artera’s established biopsy‑based MMAI model used in localized prostate cancer and was further validated in patients with mHSPC receiving ADT plus ARPI as significantly prognostic for prostate cancer–specific mortality.
"As treatment options for metastatic hormone-sensitive prostate cancer have evolved, tools to accurately assess individual patient risk in the context of modern combination therapy have not fully evolved alongside them," said Calvin Chao, MD, PhD, Vice President of Medical Science at Artera. "This clinically validated test is poised to help clinicians better tailor treatment intensity and duration to the individual patient."
The ArteraAI Prostate Test (mHSPC) is available through Artera and its commercial partner, Tempus, supporting broad and convenient access within existing clinical workflows.
(Press release, Artera, JUN 4, 2026, View Source [SID1234666452])